JADAS-10; median (IQR)a | Month 0 | Month 3 | Month 6 | Month 12 | Month 18 | Month 24 | Last observation |
 ETA | 20.8 (14; 28.4) | 6.9 (2.5; 14.3) | 6.2 (1.1; 14.7) | 3.8 (0.7; 15.7) | 4.1 (1.5; 15.2) | 3.3 (0.7; 9.4) | 9.1 (2.1; 19.1) |
 TOC | 16.9 (8.1; 24.8) | 3.6 (0.8; 10.7) | 1.5 (0.2; 3.8) | 1.6 (0.4; 6.7) | 0.9 (0.2; 2.0) | 0.9 (0.1; 7.5) | 0.9 (0.1; 4) |
 IL-1i | 13 (6.7; 20.6) | 0.8 (0.2; 1.6) | 0.6 (0.2; 2.1) | 0.8(0.2; 2.6) | 0.2 (0; 1.9) | 0.2 (0.1; 0.8) | 0.8 (0.1; 5.1) |
Patients with active systemic signs; n (%)b | Â | Â | Â | Â | Â | Â | Â |
 ETA | 2 (1%) | 0 | 0 | 2 (2.5%) | 0 | 0 | 1 (1%) |
 TOC | 30 (42%) | 5 (14%) | 3 (6%) | 3 (7%) | 2 (5%) | 1 (4%) | 4 (7%) |
 IL-1i | 40 (63%) | 9 (32%) | 8 (22%) | 8 (21%) | 8 (26%) | 4 (17%) | 6 (11%) |
Active joints; median (IQR)a | Â | Â | Â | Â | Â | Â | Â |
 ETA | 4 (2; 11) | 1 (0; 3) | 1 (0; 5) | 0 (0; 4) | 0.5 (0; 4) | 0.5 (0; 4) | 1 (0; 6) |
 TOC | 3.0 (0; 6) | 0 (0; 0.5) | 0 (0; 0.3) | 0 (0; 1.0) | 0 (0; 0) | 0 (0; 1.0) | 0 (0; 0) |
 IL-1i | 2 (0; 5) | 0 (0; 0.3) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) |
Patients with active joints; n (%)b | Â | Â | Â | Â | Â | Â | Â |
 ETA | 121 (85%) | 48 (53%) | 49 (52%) | 39 (48%) | 36 (50%) | 36 (50%) | 67 (53%) |
 TOC | 49 (69%) | 9 (26%) | 12 (25%) | 13 (29%) | 7 (19%) | 8 (29%) | 15 (21%) |
 IL-1i | 34 (60%) | 7 (25%) | 6 (17%) | 8 (21%) | 7 (23%) | 2 (9%) | 12 (21%) |
Patients on steroid use; n (%)b | Â | Â | Â | Â | Â | Â | Â |
 ETA | 119 (83%) | 66 (72%) | 73 (76%) | 48 (59%) | 36 (49%) | 35 (56%) | 65 (49%) |
 TOC | 32 (44%) | 13 (35%) | 16 (31%) | 7 (14%) | 6 (15%) | 8 (27%) | 7 (11%) |
 IL-1i | 27 (45%) | 12 (48%) | 15 (45%) | 10 (29%) | 7 (25%) | 6 (27%) | 12 (24%) |